BIOMEA FUSION INC. - COMMON STOCK
6.4400
22-11月-24 16:44:58
15 分の遅延
株式
+0.0600
+0.94%
本日の幅
6.2300 - 6.7399
ISIN
N/A
ソース
NASDAQ
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 11 2024 16:05:51 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
29 10 2024 16:46:08 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
21 10 2024 09:00:29 提供 Nasdaq GlobeNewswire
-
15 10 2024 16:05:19 提供 Nasdaq GlobeNewswire
-
07 10 2024 09:00:41 提供 Nasdaq GlobeNewswire
-
01 10 2024 09:00:01 提供 Nasdaq GlobeNewswire
-
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
26 9 2024 14:00:57 提供 Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 8 2024 16:05:20 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
31 7 2024 16:05:22 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
06 6 2024 16:05:53 提供 Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
03 6 2024 16:05:29 提供 Nasdaq GlobeNewswire
-
30 5 2024 09:12:39 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
02 5 2024 16:05:01 提供 Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 5 2024 16:10:28 提供 Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 4 2024 16:10:59 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
01 4 2024 09:02:04 提供 Nasdaq GlobeNewswire
-
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
01 4 2024 09:00:11 提供 Nasdaq GlobeNewswire
- <<
- <
- 1
- >